Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative study of efficacy and safety of Structum and Chondrosulf in patients with symptomatic osteoarthritis of the knee: a multicentre, randomised, double-blind, double placebo-controlled, parallel group study.

Trial Profile

Comparative study of efficacy and safety of Structum and Chondrosulf in patients with symptomatic osteoarthritis of the knee: a multicentre, randomised, double-blind, double placebo-controlled, parallel group study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chondroitin sulfate (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 12 May 2019 Trial completed in France. (17 Jun 2009)
    • 27 Jun 2012 Lead trial centre identified as reported by EudraCT.
    • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top